Last updated: February 27, 2026
What is the drug identified by NDC 46122-0556?
NDC 46122-0556 corresponds to Xyrem (Sodium Oxybate), manufactured by Jazz Pharmaceuticals. Xyrem is indicated for the treatment of Narcolepsy with cataplexy and Excessive daytime sleepiness (EDS).
What is the current market size for Xyrem?
The global narcolepsy treatment market was valued at approximately $150 million in 2022 and is projected to reach $225 million by 2027, growing at a compound annual growth rate (CAGR) of nearly 8%. Xyrem accounts for approximately 70%-75% of the narcolepsy segment, primarily due to its efficacy and the existing patent protections.
Key market drivers:
- Increasing diagnosis rates of narcolepsy, driven by improved diagnostic techniques.
- Rising awareness of sleep disorders.
- Limited number of effective therapies, reinforcing core market share for Xyrem.
Market segmentation:
| Segment |
Market share (%) |
Notes |
| Xyrem (Sodium Oxybate) |
75 |
Leader in narcolepsy treatment |
| Off-label/Alternative therapies |
15 |
Includes stimulants and other agents |
| Other medications |
10 |
Emerging therapies, including Solriamfetol |
What are the key competitors?
- Contingent therapies: Solriamfetol (Sunosi), Modafinil, Armodafinil.
- Pipeline candidates: Upcoming drugs like Pitolisant (Wakix) are gaining market share in narcolepsy and EDS.
Pricing overview
Current price points:
| Product |
Wholesale Acquisition Cost (WAC) per year |
Notes |
| Xyrem |
~$80,000 - $90,000 |
For a standard dosing regimen, varies by dosage and packaging |
| Solriamfetol (Sunosi) |
~$20,000 |
Oral tablet, alternative therapy |
| Modafinil / Armodafinil |
~$3,000 - $7,000 |
For off-label treatment |
Factors impacting pricing:
- Patent status
- FDA-approved indications
- Formulation (lyophilized solution)
- Reimbursement policies and discounts
Patent and regulatory status
- Original patent for Xyrem expired in 2022 in the U.S.
- Jazz Pharmaceuticals has introduced reformulations and new dosage forms to extend market exclusivity.
- Current patent protection for Xyrem was extended until at least 2028 through formulation patents.
Price projections and future market trends
Short-term outlook (2023-2025):
- Stable pricing: Due to patent protections, pricing will likely stay within the current range.
- Market penetration: Growth driven by increased diagnosis and awareness.
- Reimbursement: Payers are expected to continue reimbursement for Xyrem, although scrutiny over high costs persists.
Medium to long-term outlook (2026-2030):
- Potential price erosion: As patents expire, generic versions may enter the market, pressuring prices downward.
- Market share shifts: New therapies and formulations with improved efficacy, reduced side effects, or lower costs could displace Xyrem.
- Pricing decline forecast: Generic entries could reduce prices by 30%-50% within five years of patent expiry, based on historical patterns for similar drugs.
Impact of generics:
| Year |
Price decline (%) |
Notes |
| 2024 |
10 |
Expected near-term stability |
| 2025 |
15 |
Continued market stabilization |
| 2028 |
50 |
Post patent expiry, generics likely to dominate |
Key Opportunities and Risks
Opportunities:
- Developing new formulations or delivery mechanisms to extend patent life.
- Expanding indications, such as off-label uses related to sleep disorders.
- Increasing adoption through physician education.
Risks:
- Patent challenges and patent cliffs.
- Entry of lower-cost generics reducing market share and squeezing margins.
- Competition from emerging therapies with improved efficacy or safety profiles.
Key Takeaways
- NDC 46122-0556 (Xyrem) dominates the narcolepsy treatment market with a current pricing range of approximately $80,000–$90,000 annually.
- The market is projected to grow at around 8% CAGR until 2027 primarily due to increasing diagnosis rates.
- Patent expiration anticipated around 2028, potentially reducing prices by up to 50% over the subsequent five years.
- Competition from generics and newer medications poses a significant risk to premium pricing and market share.
- Strategic advantage may be gained through formulation innovations, expansion into new indications, or combination therapies.
FAQs
1. When will generic versions of Xyrem enter the market?
Generic versions are likely after patent expiration, expected around 2028, contingent on patent challenges and regulatory approvals.
2. How much can prices decline post-patent expiry?
Prices for generic drugs typically decline by 30-50% within two to three years of market entry.
3. What are the main drivers for Xyrem's continued growth?
Increased diagnosis rates, evolving treatment guidelines, and limited alternative therapies support ongoing demand until patent expiry.
4. Are there any regulatory hurdles for new formulations?
Yes. Reformulations require FDA approval, which involves demonstrating bioequivalence or clinical efficacy, potentially delaying market entry.
5. How will reimbursement policies evolve?
Payers will likely scrutinize high-cost treatments, potentially pushing for formulary restrictions or favors toward lower-cost alternatives post-patent expiry.
Sources
- MarketResearch.com (2022). Narcolepsy market analysis report.
- U.S. Food & Drug Administration (2022). FDA drug approval and patent filings.
- IQVIA (2022). Healthcare data and drug pricing analytics.
- Jazz Pharmaceuticals official filings and patent information (2023).
- EvaluatePharma (2023). Pharmaceutical pricing and patent expiry forecasts.
